Analysts Set Lyell Immunopharma, Inc. (NASDAQ:LYEL) Target Price at $40.86

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $40.8571.

A number of research firms recently commented on LYEL. Royal Bank Of Canada set a $34.00 target price on shares of Lyell Immunopharma in a report on Friday, August 14th. Wall Street Zen lowered Lyell Immunopharma from a “hold” rating to a “sell” rating in a report on Saturday. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. B. Riley Financial started coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a report on Friday.

Lyell Immunopharma Price Performance

Lyell Immunopharma stock opened at $11.96 on Monday. The firm’s 50-day moving average is $14.04 and its two-hundred day moving average is $17.27. Lyell Immunopharma has a 12-month low of $11.47 and a 12-month high of $45.00. The stock has a market capitalization of $293.02 million, a P/E ratio of -0.93 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, topping the consensus estimate of ($1.94) by $0.02. The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. As a group, analysts forecast that Lyell Immunopharma will post -7.2 EPS for the current year.

Institutional Trading of Lyell Immunopharma

A number of institutional investors and hedge funds have recently modified their holdings of LYEL. Renaissance Technologies LLC increased its stake in Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after acquiring an additional 76,921 shares during the period. MWG Caph Ltd bought a new position in Lyell Immunopharma in the fourth quarter valued at approximately $31,030,000. venBio Partners LLC bought a new stake in shares of Lyell Immunopharma in the second quarter worth $4,744,643. Opaleye Management Inc. raised its position in Lyell Immunopharma by 334.9% during the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after acquiring an additional 264,928 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Lyell Immunopharma during the 1st quarter worth approximately $959,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.